School of Life Science and Technology, China Pharmaceutical University, Nanjing; Shanghai Laiyi Center for Biopharmaceutical R&D.
Shanghai Laiyi Center for Biopharmaceutical R&D; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Int J Nanomedicine. 2016 Aug 12;11:3789-800. doi: 10.2147/IJN.S104166. eCollection 2016.
Acinetobacter baumannii resistance to carbapenem antibiotics is a serious clinical challenge. As a newly developed technology, silver nanoparticles (AgNPs) show some excellent characteristics compared to older treatments, and are a candidate for combating A. baumannii infection. However, its mechanism of action remains unclear. In this study, we combined AgNPs with antibiotics to treat carbapenem-resistant A. baumannii (aba1604). Our results showed that single AgNPs completely inhibited A. baumannii growth at 2.5 μg/mL. AgNP treatment also showed synergistic effects with the antibiotics polymixin B and rifampicin, and an additive effect with tigecyline. In vivo, we found that AgNPs-antibiotic combinations led to better survival ratios in A. baumannii-infected mouse peritonitis models than that by single drug treatment. Finally, we employed different antisense RNA-targeted Escherichia coli strains to elucidate the synergistic mechanism involved in bacterial responses to AgNPs and antibiotics.
鲍曼不动杆菌对碳青霉烯类抗生素的耐药性是一个严重的临床挑战。作为一种新开发的技术，与传统治疗方法相比，纳米银颗粒（AgNPs）具有一些优异的特性，是治疗鲍曼不动杆菌感染的候选药物。然而，其作用机制尚不清楚。在这项研究中，我们将 AgNPs 与抗生素联合用于治疗耐碳青霉烯类鲍曼不动杆菌（aba1604）。结果表明，单独的 2.5μg/ml AgNPs 即可完全抑制鲍曼不动杆菌的生长。AgNP 处理还与抗生素多粘菌素 B 和利福平表现出协同作用，并与替加环素具有相加作用。在体内，我们发现 AgNPs-抗生素联合治疗在鲍曼不动杆菌感染的小鼠腹膜炎模型中比单一药物治疗具有更好的生存比例。最后，我们使用不同的反义 RNA 靶向大肠杆菌菌株来阐明细菌对 AgNPs 和抗生素反应的协同机制。
Zotero 插件
